Skip to main content

EQT Life Sciences — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$3.8B
Total invested
$61.0M
Avg. check
17
Industries
Health Care 17Biotechnology 16Therapeutics 11Pharmaceutical 8Medical Device 7Medical 7+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 81
Cyted
August 2025

Cyted uses artificial intelligence (AI) and digital pathology to improve the detection and diagnosis of diseases, including cancer.

Artificial Intelligence (AI) · Cambridge$44.0M Series B
ImCheck Therapeutics
August 2024

ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.

Biopharma · Marseille$22.4M Grant
Cardior Pharmaceuticals
August 2021

Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.

Biopharma · Hanover$75.3M Series B
etherna immunotherapies
August 2022

etherna develops mRNA and lipid nanoparticle solutions.

Biotechnology · Niel$38.9M Series B
T-knife
August 2021

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.

Biotechnology · Berlin$110.0M Series B
Visus Therapeutics
August 2021

Visus Therapeutics is a clinical-stage company developing innovative medicines.

Biotechnology · Seattle$20.0M Debt Financing
Mosanna Therapeutics
June 2025

Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.

Biotechnology · Redwood City$80.0M Series A
Vico Therapeutics
June 2024

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health Care · Leiden$12.3M Series B
Ariceum Therapeutics
April 2023

Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.

Biotechnology · Berlin$25.0M Series A
Onward
April 2026

Onward develops an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools.

Biotechnology · Eindhoven$47.8M Post-IPO Equity
QurAlis
March 2023

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

Biotechnology · Cambridge$88.0M Series B
AviadoBio
March 2026

AviadoBio transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies

Biotechnology · LondonGrant
Egle Therapeutics
March 2026

Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.

Biotechnology · Paris$9.4M Grant
Neurent Medical
February 2026

Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases.

Health Care · Oranmore$74.5M Series C
Tubulis
October 2025

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

Biotechnology · Munich$400.6M Series C
SNIPR Biome
August 2025

SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.

Biometrics · Copenhagen$40.8M Series B
Neuros Medical
July 2025

Neuros Medical develops neurostimulation therapies for patients suffering with unmet medical needs.

Health Care · Willoughby$56.0M Series D
Splice Bio
June 2025

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

Biotechnology · Barcelona$135.0M Series B
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Perfuze
March 2025

Perfuze is a medical device company developing catheter-based aspiration technology to treat acute ischemic stroke.

Health Care · Newcastle$23.9M Venture - Series Unknown
VarmX
February 2025

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

Manufacturing · Leiden$15.8M Venture - Series Unknown
XyloCor Therapeutics
January 2025

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

Biotechnology · King Of Prussia$67.5M Series B
NUA Surgical
December 2024

NUA Surgical develops a specialised surgical retractor to make C-Sections a safer and superior surgery.

Cosmetic Surgery · Galway$6.9M Series A
PanTera
September 2024

PanTera produces actinium-225 for personalized cancer treatment and radiopharmaceuticals.

Health Care · Mol$110.3M Series A

Where EQT Life Sciences invests

Health Care17
Biotechnology16
Therapeutics11
Pharmaceutical8
Medical Device7
Medical7

About EQT Life Sciences's portfolio

How many companies has EQT Life Sciences invested in?

EQT Life Sciences has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does EQT Life Sciences invest in?

EQT Life Sciences's top investment sectors include Health Care, Biotechnology, Therapeutics, Pharmaceutical, Medical Device. The firm invests across 17 different industry categories.

What is EQT Life Sciences's largest investment?

Among tracked funding rounds, Tubulis received $400.6M in a Series C round. EQT Life Sciences's total known invested capital is $3.8B.

What is the average investment size for EQT Life Sciences?

EQT Life Sciences's average investment size is $61.0M across its portfolio of 81 companies.

What are EQT Life Sciences's most recent investments?

Recent EQT Life Sciences portfolio additions include Cyted, ImCheck Therapeutics, Cardior Pharmaceuticals, etherna immunotherapies, T-knife. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →